BIGBEAR
PHARMACEUTICALS
Low incidence of peripheral edema.
Low hepatotoxicity.
AuthenticGuaranteeFast DeliveryPrivacy Carmatinib is a targeted therapy for non-small cell lung cancer with MET exon 14 skipping mutations. For patients using this drug, the most crucial co···【Read More】
Update: 13 Mar,2026Source: Haiou HealthViews: 71
Carmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibitor that specifically inhibits the phosphorylation of MET receptors and···【Read More】
Update: 13 Mar,2026Source: Haiou HealthViews: 72
Copyright2024@ BIGBEAR All right reserved BIGBEAR
